Caverion Corporation's Interim Report for January 1–June

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Caverion Corporation's Interim Report for January 1–June 30, 2014: Improved working capital management – Increasing profit remains in focus

Helsinki, 2014-07-22 08:00 CEST (GLOBE NEWSWIRE) --  

CAVERION CORPORATION                INTERIM REPORT 1-6/2014             July 22, 2014 at 9:00 a.m.

Improved working capital management –  Increasing profit remains in focus
 

April 1 – June 30, 2014

  • Revenue: EUR 588.4 (652.8) million, decreased by 10 percent.
    • Revenue decreased by 7 percent at previous year’s exchange rates for corresponding period.
  • EBITDA: excluding non-recurring items EBITDA was EUR 2.9 (16.0) million, or 0.5 (2.5) percent of revenue.
    • EBITDA including non-recurring items was EUR 2.1 (12.9) million, or 0.4 (2.0) percent of revenue.
    • Activities relating to the demerger and the restructuring of the business have taken a longer time than expected and are still partly ongoing. Projects in Norway and Denmark have continued to dilute the profitability in April−June 2014. Furthermore, Caverion has reviewed the project business more closely in all the divisions and revised the cost estimates and provisions relating to some low-performing projects in the overall project portfolio. The profitability of the Norwegian project business is expected to improve during the second half of 2014.
  • Operating cash flow after investments: EUR -9.4 (-35.3) million. Improved cash flow as a result of focus on working capital management.
  • Working capital: EUR 48.6 (99.8) million at the end of June. The target to reach negative working capital by the end of 2016 is progressing according to plan.
  • Order backlog: EUR 1,350.3 (1,274.2) million at the end of June.

January 1 – June 30, 2014

  • Revenue: EUR 1,179.7 (1,260.6) million, decreased by 6 percent.
    • Revenue decreased by 3 percent at previous year’s exchange rates for corresponding period.
  • EBITDA: excluding non-recurring items EBITDA was EUR 16.0 (28.2) million, or 1.4 (2.2) percent of revenue.
    • EBITDA including non-recurring items was EUR 11.7 (22.3) million, or 1.0 (1.8) percent of revenue.
    • EBITDA is burdened by non-recurring items of EUR -4.3 million in total. The non-recurring costs of EUR 17.5 million consisted of expenses relating to a terminated M&A project, reorganisation costs and provisions for old, completed projects , including a final settlement of EUR 3.5 million from an old export project in Danish operations due to bankruptcy of a joint venture partner. These were offset by a non-recurring release of pension liability to pension costs of EUR 13.2 million following a transfer into a new pension scheme in Norway.
  • Operating cash flow after investments: EUR -26.3 (-37.5) million, burdened by IT license prepayments of EUR 4.3 million and a non-recurring payment of EUR 3.5 million related to a final settlement in Denmark. Investments of EUR 8.2 million in January–June related mainly to IT and development of common business processes. 

Unless otherwise noted, the figures in brackets refer to the corresponding period in the previous year. Comparative figures for 2013 are carve-out figures for the periods before the effective date of the partial demerger (June 30, 2013).

KEY FIGURES

EUR million 4-6/14 4-6/13 Change 1-6/14 1-6/13 Change 1-12/13
Revenue 588.4 652.8 -10% 1,179.7 1,260.6 -6% 2,543.6
EBITDA 2.1 12.9 -84% 11.7 22.3 -48% 70.9
EBITDA margin, % 0.4 2.0   1.0 1.8   2.8
EBITDA excl. non-recurring items 2.9 16.0 -82% 16.0 28.2 -43% 81.7
EBITDA margin excl. non-recurring items, % 0.5 2.5   1.4 2.2   3.2
Operating profit -3.6 7.8   0.4 12.1 -97% 49.4
Operating profit margin, % -0.6 1.2   0.0 1.0   1.9
Net profit for the period -4.1 4.2   -2.3 7.0   35.5
Earnings per share, basic, EUR -0.03 0.03   -0.02 0.06   0.28
               
Working capital 48.6 99.8 -51% 48.6 99.8 -51% 46.0
Operating cash flow after investments -9.4 -35.3   -26.3 -37.5   74.2
               
Interest-bearing net debt, end of period 142.5 194.0 -27% 142.5 194.0 -27% 86.5
Gearing, end of period, % 64.8 85.5   64.8 85.5   34.6
               
Personnel, average for the period 17,333 18,106 -4% 17,354 18,229 -5% 18,071

Word from the President and CEO Fredrik Strand

“The work to move from the old YIT financial holding model into a competitive coherent service and project corporation with common processes and tools is progressing well with full speed.

During April–June we have reviewed our overall project portfolio more closely in all the divisions and revised the cost estimates and provisions relating to some low-performing projects. The review has negatively impacted the reported EBITDA and the EBITDA full year guidance due to cost estimate adjustments to projects in the completion phase, provisions made for low-performing active projects and provisions made for old, completed projects. The latter has been considered as non-recurring items as defined in the financial tables under note 5. Caverion is conservative in defining non-recurring items, which are excluded from our EBITDA guidance.

Our Q2 results should be seen as an integrated part of our overall performance and part of completing the demerger and restructuring of the operations within Caverion and not an individual quarter as projects typically stretch over 12-24 months.

We are still in progress in increasing our profitability. This is the foundation we need in order to achieve growth in line with our vision: to become a leading European provider of advanced and sustainable life cycle solutions for buildings and industries.

We also strive to have more efficient and harmonised processes in all our countries. Having the best people is not enough, if the processes and tools supporting their work are not sufficient. We have therefore initiated process development and it is our firm goal to have all the redefined processes in place as by the end of the year.

In addition, we are investing in tools and templates to shorten the invoicing process. Our improved working capital management is already bearing fruit, which can be seen in our improved cash flow from operations for April–June.”

OUTLOOK FOR 2014

Market outlook for Caverion’s services

There are no changes to the previously communicated market outlook.

The increase of technology in buildings, energy efficiency requirements, increasing digitalisation and automation all promote demand for Caverion’s services over the coming years. The opportunities to grow in service and maintenance business are still favourable in all of Caverion’s divisions in 2014. As technology in buildings is increasing the need for new services and the demand for life cycle solutions are expected to increase. New investments in building systems are expected to increase slightly and positive signs can be seen in tendering activity. The growing public investments and the need for renovation and repair work are expected to be the key factors behind the growth. The tightening of environmental legislation will improve the growth potential of energy efficiency services. Environmental certifications and energy efficiency will be significant factors that will allow the property owners to upgrade their property value. An increasing number of properties will be connected to remote monitoring through command centres.

Guidance for 2014

Caverion updated its guidance for 2014 on July 14, 2014. According to the updated guidance Caverion estimates that the Group’s revenue with comparable exchange rates and EBITDA excluding non-recurring items for 2014 will remain at the previous year's level.

In 2014 the targeted EBITDA level will be reached by improving the operational efficiency, growing the service and maintenance business as well as increasing the project business in Germany. The potential changes in general macroeconomic environment nonetheless may have an effect on Caverion’s business and customers.

One single operative segment

The Board of Directors of Caverion Corporation decided on 27 January, 2014 that Caverion’s external reporting structure will be changed as of January 1, 2014 to better match the company’s new management structure and business areas. The segments based on geographical areas (Building Services Northern Europe and Building Services Central Europe) are replaced by one single operative segment, that will also include the Group services and other items. Since Caverion’s establishment, both service and maintenance and project businesses have been developed strongly across all countries. This interim report is the second one based on the new reporting structure. The change in reporting structure has no effect on the Group’s strategic targets.

INFORMATION SESSION, WEBCAST AND CONFERENCE CALL


Caverion will hold a news conference and webcast on the Interim Report on Tuesday, July 22, 2014, at 11:00 a.m. (Finnish Time, EEST) at the Kämp Hotel (Gallen-Kallela meeting room), Kluuvikatu 2, Helsinki, Finland. The news conference can also be viewed live on Caverion’s website at www.caverion.com/investors. It is also possible to participate in the event through a conference call by calling the assigned number +44 207 660 2078 (no conference ID or pin code required) at 10:55 a.m. (Finnish time, EEST) at the latest. More practical information on the news conference can be found on Caverion's website, www.caverion.com/investors .

Other IR events in 2014

Caverion will arrange a Capital Markets Day in Stockholm on September 10, 2014 at 9:00 a.m. (Swedish Time, CEST). More information on the programme has been published as a stock exchange release on June 18, 2014.

Financial information in 2014

Interim Report for January - September will be published on October 31, 2014 at 9:00 a.m. (Finnish Time, EET).

Financial reports and other investor information are available at Caverion's website, www.caverion.com/investors , and IR App. The materials may also be ordered by sending an e-mail to IR@caverion.com.


CAVERION CORPORATION


 

For further information, please contact:


Antti Heinola, Chief Financial Officer, Caverion Corporation, tel. +358 40 352 1033, antti.heinola@caverion.fi

Milena Hæggström, Head of Investor Relations, Caverion Corporation, tel. +358 40 5581 328, milena.haeggstrom@caverion.fi



Distribution: NASDAQ OMX Helsinki, principal media, www.caverion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading